# A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

> **NCT01144364** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 234 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** rituximab [Mabthera/Rituxan]

## Key facts

- **NCT ID:** NCT01144364
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01-19
- **Primary completion:** 2011-07-21
- **Final completion:** 2011-07-21
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2017-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01144364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01144364, "A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01144364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*